Expression of Protein 4.1 Family in Breast Cancer: Database Mining for 4.1 Family Members in Malignancies

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2019 May 8

PMID 31063460

Citations 6

Authors

Guan Feng

Kaibo Guo

Qingying Yan

Ye Ye

Minhe Shen

Shanming Ruan

Shengliang Qiu

Affiliations

Soon will be listed here.

Abstract

BACKGROUND The protein 4.1 family is a family of cytoskeletal proteins that play an important role in maintaining normal cell morphology and cell adhesion, migration, division, and intercellular signaling. The main aim of this study was to explore the prognostic significance of the protein 4.1 family in breast cancer (BC) patients and to provide new biomarkers and therapeutic targets for the diagnosis and treatment of BC. MATERIAL AND METHODS The expression of 4.1 family members in various tumor types was compared to normal controls using the ONCOMINE and GOBO databases. The prognostic significance of the 4.1 family in BC patients was determined by Kaplan-Meier Plotter. RESULTS EPB41L2 (4.1G) was expressed at higher levels in normal tissues compared with BC patients for all 4.1 family members. In survival analysis, 4.1G and EPB41 (4.1R) mRNA high expressions were associated with better survival in BC patients. Moreover, 4.1G high expression was significantly associated with longer overall survival (OS) in luminal A and protracted relapse-free survival (RFS) in luminal B subtype BC patients who received Tamoxifen treatment. In addition, high expression of each 4.1 family member also showed better prognostic value in different molecular subtypes of BC. CONCLUSIONS These results indicate that the protein 4.1 family can be regarded as novel biomarkers and potential therapeutic targets for BC. Further research is needed to explore the detailed biological functions.

Citing Articles

Analysis of serum peptidome profiles of non-metastatic and metastatic feline mammary carcinoma using liquid chromatography-tandem mass spectrometry.

Paphussaro W, Roytrakul S, Phaonakrop N, Buthasane W, Rungsipipat A, Tharasanit T BMC Vet Res. 2024; 20(1):280.

PMID: 38951817 PMC: 11218297. DOI: 10.1186/s12917-024-04148-y.

Cytoskeletal Protein 4.1R in Health and Diseases.

Liu J, Ding C, Liu X, Kang Q Biomolecules. 2024; 14(2).

PMID: 38397451 PMC: 10887211. DOI: 10.3390/biom14020214.

Identification of Genetic Risk Factors for Keratinocyte Cancer in Immunosuppressed Solid Organ Transplant Recipients: A Case-Control Study.

Sunder-Plassmann R, Geusau A, Endler G, Weninger W, Wielscher M Cancers (Basel). 2023; 15(13).

PMID: 37444464 PMC: 10340609. DOI: 10.3390/cancers15133354.

4.1N-Mediated Interactions and Functions in Nerve System and Cancer.

Yang Q, Liu J, Wang Z Front Mol Biosci. 2021; 8:711302.

PMID: 34589518 PMC: 8473747. DOI: 10.3389/fmolb.2021.711302.

Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.

Yu S, Hu C, Liu L, Cai L, Du X, Yu Q J Transl Med. 2020; 18(1):286.

PMID: 32723333 PMC: 7388537. DOI: 10.1186/s12967-020-02454-1.

References

Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D . Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005; 24(29):4660-71. DOI: 10.1038/sj.onc.1208561. View

Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J . GOBO: gene expression-based outcome for breast cancer online. PLoS One. 2011; 6(3):e17911. PMC: 3061871. DOI: 10.1371/journal.pone.0017911. View

Scimeca M, Urbano N, Bonfiglio R, Schillaci O, Bonanno E . Breast osteoblast-like cells: a new biomarker for the management of breast cancer. Br J Cancer. 2018; 119(9):1129-1132. PMC: 6219492. DOI: 10.1038/s41416-018-0255-y. View

Nagata M, Sakurai-Yageta M, Yamada D, Goto A, Ito A, Fukuhara H . Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma. Int J Cancer. 2011; 130(6):1329-37. DOI: 10.1002/ijc.26160. View

Bazzini C, Benedetti L, Civello D, Zanoni C, Rossetti V, Marchesi D . ICln: a new regulator of non-erythroid 4.1R localisation and function. PLoS One. 2014; 9(10):e108826. PMC: 4189953. DOI: 10.1371/journal.pone.0108826. View

Men Y, Kang Q, Ding C, Liu S, Jiang H, Wang X . [Expression of protein 4.1 family in melanoma cell lines and its effect on cell proliferation]. Nan Fang Yi Ke Da Xue Xue Bao. 2016; 36(5):649-54. View

Lanczky A, Nagy A, Bottai G, Munkacsy G, Szabo A, Santarpia L . miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016; 160(3):439-446. DOI: 10.1007/s10549-016-4013-7. View

Jung Y, McCarty J . Band 4.1 proteins regulate integrin-dependent cell spreading. Biochem Biophys Res Commun. 2012; 426(4):578-84. PMC: 3467326. DOI: 10.1016/j.bbrc.2012.08.129. View

Zhang J, Yang S, An C, Wang J, Yan H, Huang Y . Comprehensive characterization of protein 4.1 expression in epithelium of large intestine. Histochem Cell Biol. 2014; 142(5):529-39. DOI: 10.1007/s00418-014-1224-z. View

10.

Cui J, Huang W, Wu B, Jin J, Jing L, Shi W . N-glycosylation by N-acetylglucosaminyltransferase V enhances the interaction of CD147/basigin with integrin β1 and promotes HCC metastasis. J Pathol. 2018; 245(1):41-52. PMC: 5947728. DOI: 10.1002/path.5054. View

11.

Robb V, Li W, Gascard P, Perry A, Mohandas N, Gutmann D . Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis. Neurobiol Dis. 2003; 13(3):191-202. DOI: 10.1016/s0969-9961(03)00071-8. View

12.

Xi C, Ren C, Hu A, Lin J, Yao Q, Wang Y . Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer. Gynecol Oncol. 2013; 131(3):764-71. DOI: 10.1016/j.ygyno.2013.08.015. View

13.

Ruiz-Saenz A, van Haren J, Sayas C, Rangel L, Demmers J, Millan J . Protein 4.1R binds to CLASP2 and regulates dynamics, organization and attachment of microtubules to the cell cortex. J Cell Sci. 2013; 126(Pt 20):4589-601. DOI: 10.1242/jcs.120840. View

14.

van de Rest O, Berendsen A, Haveman-Nies A, de Groot L . Dietary patterns, cognitive decline, and dementia: a systematic review. Adv Nutr. 2015; 6(2):154-68. PMC: 4352174. DOI: 10.3945/an.114.007617. View

15.

Scimeca M, Antonacci C, Toschi N, Giannini E, Bonfiglio R, Buonomo C . Breast Osteoblast-like Cells: A Reliable Early Marker for Bone Metastases From Breast Cancer. Clin Breast Cancer. 2018; 18(4):e659-e669. DOI: 10.1016/j.clbc.2017.11.020. View

16.

Sun C, Robb V, Gutmann D . Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci. 2002; 115(Pt 21):3991-4000. DOI: 10.1242/jcs.00094. View

17.

Chen L, Wang T, Wang Y, Zhang J, Qi Y, Weng H . Protein 4.1G Regulates Cell Adhesion, Spreading, and Migration of Mouse Embryonic Fibroblasts through the β1 Integrin Pathway. J Biol Chem. 2015; 291(5):2170-80. PMC: 4732203. DOI: 10.1074/jbc.M115.658591. View

18.

Lv B, Ma L, Tang W, Huang P, Yang B, Wang L . FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition. Cell Physiol Biochem. 2018; 48(1):158-172. DOI: 10.1159/000491715. View

19.

Cheng C, Molday R . Interaction of 4.1G and cGMP-gated channels in rod photoreceptor outer segments. J Cell Sci. 2013; 126(Pt 24):5725-34. PMC: 3860314. DOI: 10.1242/jcs.137679. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View